Hikma Pharmaceuticals Receives IFC Client Leadership Award

Tokyo, 14 October 2012 – Hikma Pharmaceuticals PLC (LSE: HIK) (NASDAQ Dubai: HIK), the fast growing multinational pharmaceutical group, today received the 2012 Client Leadership Award presented by the IFC, a member of the World Bank Group. Sustainable development initiatives, quality standards in operations and excellence in corporate governance were key to receiving this award.

Press Release Corporate 14 October 2012

Hikma Vice-Chairman and CEO of MENA Mazen Darwazah accepted the award from IFC CEO and Executive Vice President Jin-Yong Cai during the World Bank-IMF annual meeting in Tokyo on October 14th. Hikma was recognized for its success in helping to treat patients in more than 50 countries through the providing vital affordable medicines. It was also recognized for its commitment to local communities - as an employer of more than 6,500 people, for its support for female workers, for its commitment to applying high environmental standards in production and for its commitment to education and training, especially through the offering internships for young people.

“This is award is a testament to the work we have done over the last 30 years to turn Hikma into a world-class company,” said Darwazah. “I think it also shows that companies that focus on being good corporate citizens will also have success.”

Hikma and IFC have a long standing relationship that began in 1987. Over the years, IFC has provided financing for Hikma as well as advisory services in corporate governance, environmental management and community welfare.

“Hikma is not only providing affordable medicines to millions—it is also setting the standard for corporate social responsibility in the Middle East and North Africa,” Cai said. “Our partnership of more than 20 years with Hikma demonstrates how the private sector can spark change in the region and make a difference in people’s lives.”

Important notice for users

You are about to access Hikma historic archive material. Any reference in these archives to Hikma products or their uses may not reflect current medical knowledge and should not be used as a source of information on the present product label, efficacy data, or safety data. Please refer to your approved national product label (SmPC) for current product information.

I have read this warning and will not be using any of the contained product information for clinical purposes.